As opposed to in HNSCC, p53 is not oftentimes mutated in salivary gland cancers, and a major therapeutic strategy that has since been translated into clinical trials involves targeting the MDM2-p53 interaction. The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.